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Summary
 Aim Dose distribution was compared between two alternative methods for the brachy-
therapy of tumours of the CNS: conventional implants which complied with the 
regulations of the Paris system and stereotactic implants. A biological model was 
analysed in stereotactic implants.
 Materials/Methods 31 sequential stereotactic CNS tumour implants were analysed. The analysed im-
plants were compared with appropriate hypothetical implants designed accord-
ing to the classic standards of the Paris system. Physical parameters of Dose dis-
tribution were analysed, including: coverage index (CI), conformity factor (CF), 
high dosage treatment volume (V200), and minimum dose. A value for the radi-
obiological parameter – Equivalent Uniform Dose (EUD) – was calculated.
 Results In comparison with classic Paris System implants, stereotactic implants affected 
only half the volume of healthy tissue within the area of the reference isodose, 
though the high dose volume was greater. EUD was sensitive to changes in min-
imal dose and coverage index CI.
 Conclusions This parameter may be a criterion in the optimization of dose distribution in ra-
diotherapy.
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BACKGROUND
Optimal radiotherapy is a treatment, which gives 
individual patients the highest likelihood of a lo-
calised cure (TCP) and the lowest risk of injury to 
healthy tissues (NTCP). The parameters TCP and 
NTCP should be ideal criteria for the optimiza-
tion of dose distribution, however the models thus 
far proposed are mathematically complex and dif-
ﬁ cult to apply. In clinical practice the bases on 
which treatment plans are assessed are the phys-
ical parameters of dose distribution. Niemierko 
proposed a uniform dose distribution parameter 
for radiotherapy – the Equivalent Uniform Dose 
(EUD) which may be acceptable as a biological 
model suitable for use in irradiation [1].
In classic brachytherapy, implants comprising of 
radium needles or iridium wire are introduced 
into the tissues, implants are limited and regulat-
ed by the brachytherapy systems. Brachytherapy 
using a radiation source of high activity (HDR) 
and stereotactic technique represent impor-
tant progress in comparison to the classic form. 
Thanks to stereotactic equipment, isotopes may 
be precisely introduced to the area to be irradi-
ated, under control of computed tomography 
(CT) or magnetic resonance imaging (MRI). 
Altering the times for which the source is held 
at each consecutive position allows the modelling 
of dose distribution. CNS tumour brachythera-
py is a speciﬁ c form of interstitial brachytherapy 
used when protection of nearby healthy tissues 
in critical organs is necessary.
AIM
The purposes of the study are:
1. To compare physical dose distribution in the 
brachytherapy of tumours of the nervous tis-
sues by two alternative methods:
 a)  conventional implants which comply with 
the speciﬁ cations of the Paris System;
 b) stereotactic implants.
2. To deﬁ ne radiobiological parameters for the 
assessment of a model reaction of the tissues 
in stereotactic implants.
MATERIALS AND METHODS
31 consecutive stereotactic implantations in cas-
es of brain tumours were analysed in the years 
1998–2000. Implantation was carried out using 
two guides. The therapeutic dose in planning 
target volume amounted to 15 Gy (5 fractions 
at 3 Gy daily). The median volume of tumours, 
including 5 mm margins (VPTV) amounted to 78 
cm3. The minimum planning target volume was 
33 cm3, and the maximum was 177 cm3.
Implants compliant with the Paris System
Based on the shape of the area to be irradiated, 
which was deﬁ ned on the basis of CT and MRI im-
ages, a hypothetical implant was designed, accord-
ing to the classical rules of the Paris System [2]. 
The internal volume of the reference isodose of 
the Paris System implant (VPS) was calculated on 
the basis of a cuboid placed in the region to be 
irradiated. Figure 1 illustrates the ideal deﬁ nition 
of the reference volume of a “Paris” implant (sim-
pliﬁ ed for presentation in two dimensions).
Stereotactic implants
The shape of the tumour was reconstructed on the 
basis of MRI images. Thanks to fusion of MRI and 
CT images (CT tests carried out using stereotactic 
methods) the positions of all anatomical points 
could be entered into the coordinates of the ster-
eotactic frame, thus allowing for the positioning 
of isotopes along the planned trajectory.
Stereotactic implants were planned according to 
the following rules:
1.  At least 95% of the planning target volume 
must receive the therapeutic dose.
2.  Bordering volumes of healthy tissues should 
not receive doses higher than the therapeu-
tic dose and should not have been more than 
minimally damaged surgically.
3.  Areas receiving higher doses, such as those re-
ceiving doses greater than twice the therapeu-
tic dose must be limited.
Figure 2 (left side) shows the implanted guide 
of the source, the contours of the planning tar-
get volume, the eyeballs and stereotactic mark-
ers. On the right, the guide are presented, with 
the source positions marked.
Physical parameters of stereotactic and Paris 
System implants
Minimal dose
In agreement with the rules of the Paris System, 
it was accepted that the reference isodose con-
sists of the whole planning target volume and 
the minimum dose in a hypothetical “Paris” im-
plant should be equal to the therapeutic dose, 
amounting to 15 Gy.
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For the calculation of dose distribution with 
stereotactic implants, the PLATO (version 14.1 
– Nucletron) and Target (version 16 – BrainLab) 
treatment planning systems were used. The mini-
mum dose in planning target volume is the small-
est dose in an element 1 mm3 in volume (Dmmmin). 
Also deﬁ ned were doses characteristic for every 
1 cm3 of the planning target volume, within the 
area of the lowest dose (Dcmmin). Values for 1 cm3 
volumes were calculated by addition of values for 
1000 volume elements of 1 mm3, receiving the 
smallest dose, Dcmmin, as follows:
  
1000
Dcmmin =
 SD(mm)i
             i=1
1000
Coverage Index (CI)
The coverage index (CI) parameter shows the 
fraction of the planning target volume which will 
receive at least the therapeutic dose [3]. The CI 
of hypothetical “Paris” implants has been estab-
lished as an even 100%.
Conformity Factor (CF)
The conformity factor (CF) of dose distribution 
describes the volume of healthy tissue which is ir-
radiated with a dose not less than the therapeutic 
dose [3]. CF is deﬁ ned as the volume of healthy tis-
sue receiving a dose not less than the therapeutic 
dose divided by the total planning target volume 
and receiving a dose not less than the therapeutic 
dose. The conformity factor CFPS of a hypothetical 
Paris System implant is deﬁ ned as the estimated 
reference volume of the “Paris” implant (VPS) di-
vided by the planning target volume(VPTV).
High dosage volume
The high dosage volume is the volume receiv-
ing a dose at least twice as great as the therapeu-
tic dose. The high dosage volume is annotated 
as V200 (for stereotactic implants) or VPS200 (for 
“Paris” implants). On the basis of analysed dose 
distribution from Paris System implants, it was as-
sumed that the high dosage volume, of “Paris” 
implants investigated, amounted to 18% of the 
reference volume VPS.
Equivalent Uniform Dose (EUD)
EUD of non-uniform dose distribution is deﬁ ned 
as the uniform dose which gives the same fraction 
of surviving tumour cells as the non-uniform dose 
(we set up an identical fractionation scheme for 
both dose distribution). Knowing the dependen-
cy between the fraction of surviving tumour cells 
from dose SF(D) and differential histograms for 
dosage spread {Di,Vi} in the planning target vol-
ume V, EUD can be calculated as:
              SF(EUD)=S(Vi/V)*SF(Di) (1)
EUD may be determined by two methods, taking 
into consideration two SF(D) models.
EUD1 (“one shot” model)
In accordance with the most simple model, the 
relationship between the fraction of surviving ne-
oplastic cells and radiation dose is [4]:
Figure 1. A diagram showing the reference volume of a Paris 
System implant (VPS) based on planning target volume (VPTV).
Figure 2. Diagram of a planned implantation: left side: guide on 
a background with the tumour, eye balls and stereotactic markers; 
on the right: guides with marked source positions, arranged along 
the longest axis of the tumour.
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                      SF(D) = exp(-D/Do) (2)
where Do is the dose after which 37% of cells 
survive. This relationship may be represented as 
SF(D)=SF(2)D/2Gy because SF(2)=exp(-2Gy/Do). 
SF(2) is the fraction of cells surviving a radiation 
dose of 2 Gy. Thus:
                  SF(EUD) = SF(2)EUD/2Gy (3)
From relationship (1) we obtain:
SF(2)EUD/2Gy = S(Vi/V)SF(Di) = S(Vi/V)SF(2)Di/2Gy (4)
 EUD1 = 2Gy*ln(S(Vi/V)SF(2)
Di/2Gy)/lnSF(2) (5)
The value for EUD1 was accepted as SF(2)=0.5.
EUD2 (linear-quadratic model)
According to the linear-quadratic model, and con-
sidering dose fractionation, the function SF(D) 
is deﬁ ned as follows:
                  SF(D)= exp(-aD -bD2/n)) (6)
where n is the number of fractions and a and b 
are parameters for a given tissue.
SF(EUD)= exp(-aEUD -bEUD2/n)
From relationship (1) we obtain:
          -aEUD -bEUD2/n = ln( SFtotal) (7)
where the total fraction of surviving cells in the 
given area SFtotal amounts to:
  SFtotal=S(Vi/V)SF(Di))=S(Vi/V)exp(-aDi -bDi2/n)) (8)
Relationship (7), on the basis of which EUD is 
deﬁ ned, is a quadratic equation. Resolving this 
equation we obtain:
EUD2 = n/2 [-a/b+(a2/b2–4ln(SFtotal)/nb)1/2] (9)
For the purpose of deﬁ ning EUD2 the values for 
a and b were accepted as 0.35 and 0.035. For cal-
culation purposes, it was accepted that the dose 
immediately around the source is no greater than 
600% of the therapeutic dose. Preliminary cal-
culations proved that this assumption does not 
alter the values of EUD1 and EUD2.
RESULTS
Coverage index and minimal dose
In “Paris” implants, the minimal dose amounts 
to 15 Gy and the coverage index is accepted as 
100%.
Median CI for stereotactic implants amount-
ed to 96%. Table 1 shows the basic parameters 
of spread Dmmmin and Dcmmin for these implants. The 
correlation coefﬁ cient between Dmmmin and Dcmmin was 
r=0.83 (p<0.001). The average minimal dose for 
internal Dmmmin volumes irradiated was 67% of the 
therapeutic dose. In one case the dose barely 
reached 45% of the therapeutic dose. The aver-
age minimal dose, characteristic for 1 cm3 – Dcmmin 
volumes – was signiﬁ cantly greater and amount-
ed to 87% of the therapeutic dose.
Figure 3 shows values for Dmmmin and Dcmmin from 31 
analysed stereotactic implants, sorted accord-
ing to increasing coverage index. The relation-
ship between the parameters CI and Dcmmin (r=0.82, 
(%
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Figure 3. Dmmmin  and Dcmmin  values of stereotactic implants, sorted 
according to increasing coverage index.
 Minimum Maximum Average SD
Dmin
mm 45.0% 84.0% 66.6% 9.2%
Dmin
cm 72.0% 106.2% 86.6% 8.4%
Table 1. Dosage parameters Dmmmin  and Dcmmin  in stereotactic implants. Dose expressed as a percentage of the total therapeutic dose.
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p<0.001) is stronger than that between CI and 
Dmmmin (r=0.61, p<0.001), though the difference be-
tween these two correlation coefﬁ cients is not sta-
tistically signiﬁ cant.
Conformity Factor
Table 2 shows conformity factor values for ster-
eotactic and Paris System implants. The average 
CF value was 1.79 (SD±0.23), and the average 
CFPS value was 2.71 (SD±0.40). There was a posi-
tive correlation between the parameters CF and 
CFPs (r=0.39, p=0.03).
High dosage volume
The parameters V200 and VPS200 showed normal 
distribution, which is shown in the histogram in 
Figure 4. Table 3 shows the basic spread parame-
ters V200 and VPS200. The average size of the high 
dosage volume for clinical implants is greater 
than the average high dosage volume for “Paris” 
implants by 31%. The correlation coefﬁ cient be-
tween parameters V200 and VPS200 was found to 
be r=0.88, (p<0.001).
Equivalent Uniform Dose (EUD)
Table 4 shows the average values, ranges and 
standard deviations for the parameters EUD1 
and EUD2. The average value for EUD1 was 13% 
higher than the average value for EUD2. Both 
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Figure 4. A histogram showing high dosage volumes for 
stereotactic implants (V200), Paris System implants(VPS200) and 
normal distribution for these parameters.
Minimum Maximum Average SD
EUD1 (Gy) 18.3 23.0 20.6 1.1
EUD2 (Gy) 15.1 20.4 18.3 1.1
Table 4. Average values, intervals and standard deviations for parameters EUD1 and EUD2.
Minimum Maximum Average SD
V200 (cm
3) 20.0 105.0 54.6 19.5
V200PS (cm
3) 11.2 81.2 41.8 15.5
Table 3. Average values, intervals and standard deviation for parameters V200 and VPS200.
Minimum Maximum Average SD
CF 1.37 2.37 1.79 0.22
CFPS 1.94 3.69 2.71 0.40
Table 2. Average values, intervals and standard deviation for CF and CFPS.
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these average values (EUD1 and EUD2) are great-
er than the appropriate therapeutic dose of 15Gy 
by 37% and 22% respectively.
Figure 5 shows the parameters EUD1 and EUD2 
for analysed cases, sorted according to increas-
ing minimal doses.
Table 5 shows values for the linear correlation co-
efﬁ cient r between physical dose distribution pa-
rameters CI, Dmmmin and Dcmmin and the radiobiological 
parameters EUD1 and EUD2; all values are statis-
tically signiﬁ cant (p<0.001).
From Table 5 it can be seen that the parameters 
EUD1 ind EUD2 both show a greater correlation 
with dose Dcmmin than with minimal dose Dmmmin. The 
correlation coefﬁ cients between EUD1, and min-
imal dose and between EUD1 and dose D
cm
min were 
r=0.77 and r=0.87 respectively. The difference be-
tween these two correlation coefﬁ cients was not 
statistically signiﬁ cant, however. Likewise, the de-
pendency of EUD2 on D
cm
min (r=0.89) was strong-
er than the association between EUD2 and D
mm
min 
(r=0.73).
DISCUSSION
Analysis of the physical parameters of 
stereotactic and Paris System implants
Coverage Index and Conformity Factors allow us 
to assess a basis of radiotherapy; CI deﬁ nes the 
proportion of a volume of tissue receiving a suit-
able radiation dose and CF represents the quan-
tity of healthy tissue irradiated. For external ra-
diotherapy, in accordance with ICRU report 50, 
the parameter CI may be less than 100% [5]. CI 
is associated with the minimal dose in the plan-
ning target volume. Years of radiotherapy have 
led to the formation of a hypothesis that, in the 
case of dose distribution with a high degree of 
non-uniformity, effective dose is dependent on 
the settling of minimum dose [6]. In brachy-
therapy, owing to dosage gradients, the value 
for “minimal dose” is associated with the size of 
analysed “voxel” elements. The correlation be-
tween the parameters Dmmmin and CI for analysed 
implants (r=0.6, p<0.001) ﬁ xed CI as a criteri-
on for optimising dosage spread. Dmmmin amount-
ed to an average of 67%, though in one case the 
dose attained hardly reached 45% of the ther-
apeutic dose, resulting in the deﬁ nition of cri-
terion CI as ≥95% and a large dosage gradient. 
Values for Dmmmin do not fulﬁ l the criteria of ICRU 
report number 50, which is used in external ra-
diotherapy [5].
3D interstitial brachytherapy planning is the sub-
ject of the AAPM report of 1997 [7]. The authors 
claim that, in traditional brachytherapy planning, 
the red minimal dose. received by an irradiated 
volume is, on average, half the dose assumed as 
minimum dose. This is in agreement with the re-
sults of our study. The report suggests limits on 
CI values, which are historically linked with dos-
es and volumes applied before.
CI EUD1 EUD2 Dmin
mm Dmin
cm
CI 1.00 0.82 0.90 0.61 0.82
EUD1 0.82 1.00 0.97 0.77 0.87
EUD2 0.90 0.97 1.00 0.73 0.89
Dmin
mm 0.61 0.77 0.73 1.00 0.83
Dmin
cm 0.82 0.87 0.89 0.83 1.00
Table 5. Linear correlation coeﬃ  cients r between parameters CI, Dmmmin , Dcmmin , EUD1 and EUD2 for stereotactic implants, (p<0.001 in all 
cases).
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Figure 5. EUD1 and EUD2 for analysed cases, sorted according to 
increasing minimal doses Dmmmin .
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Because parameters CI and CF are normalized 
to the planning target volume, the range of val-
ues for VPTV is wide (33–177 cm
3) and, therefore, 
the same CI or CF values may have different clin-
ical signiﬁ cance for different implants.
Parameters CI and CF are used to assess dose dis-
tribution – though only from discreet points on 
the histograms for planning target volume and 
healthy tissues. In spite of having full DVH his-
tograms at our disposal, we did not use this in-
formation.
From a comparison of conformity factors for ster-
eotactic implants (average value: CF=1.79) and 
hypothetical Paris System implants (average val-
ueCFPS=2.71) it can be seen that “Paris” implants 
deliver the therapeutic dose to twice as much vol-
ume of healthy tissue as do stereotactic implants. 
Because the average value for VPTV amounts to 
91 cm3, classic Paris System implants can not pos-
sibly be acceptable for CNS brachytherapy.
The high dosage volume for stereotactic im-
plants is greater than in equivalent “Paris” im-
plants, which results from uneven positioning 
of guides. Many publications underline that the 
likelihood of necrosis is increased in the high 
dosage volume [8,9], although authors of oth-
er works claim there are positive effects of high 
doses in the centre of tumours in case of hypox-
ic tissues [10,11].
Analysis of radiobiological parameters in 
stereotactic implants
Various methods are used, for the reduction of 
data contained in histograms, in order to deﬁ ne 
TCP and NTCP and for transforming physical 
dosage to its biological effects. It is important to 
point out that TCP and NTCP are mathemati-
cally complicated and therefore attempts to op-
timize dosage spread in relation to these param-
eters have limited usefulness [12]. An alternative 
could be optimisation on the basis of EUD [13]. 
The parameter EUD “reduces” histogram DVH 
and, at the same time, allows for assessment of 
dose distribution according to biological effects. 
EUD is highly sensitive to minimum dose (for 
implants analysed r=0.8), and therefore may be 
used to assess effective dose. EUD is always greater 
than the minimal dose. For dose distribution an-
alysed, EUD was always greater than the planned 
therapeutic dose of 15 Gy – average EUD1 and 
EUD2 amount to 20.6 Gy and 18.3 Gy respectively. 
Niemierko deﬁ ned EUD for dose distribution in 
external radiotherapy and, in the majority of cas-
es, EUD was less than the therapeutic dose [1]. 
Fowler suggests, however, that EUD should also 
be compared with therapeutic doses [14].
Therapeutic doses in analysed implants amount-
ed to 15Gy and EUD values (deﬁ ned on the ba-
sis of the LQ model) range from 15.1 Gy to 20.4 
Gy. EUD could be suitable for settling the thera-
peutic dose in brachytherapy, where “hot” areas 
appear in the high dose volume. EUD, like TCP, 
has limited sensitivity to maximum dose. This is 
the result of the sigmoid shape of the function 
formed by TCP ~ exp (-exp (-D)).
It is an interesting fact that EUD shows a greater 
correlation with minimal dose, characterised by 
1 cm3 volumes analysed (r=0.9), than with mini-
mal doses in 1 mm3 (r=0.8) volumes. Could it be 
that discreet “cold points” of minimal size have 
no fundamental inﬂ uence on total biological ef-
fects? Intuitively we may assume that the effects 
of irradiation depend, not only on the minimal 
dose, but also on the size of the “cold” volume.
The correlation coefﬁ cient between EUD and 
coverage index CI (r=0.9) is greater than that be-
tween EUD and minimum dose (r=0.8). Could it 
be that coverage index is a more suitable criteri-
on for optimisation than minimal dose?
Values for the parameter EUD depend on the ac-
cepted function for dose – effect. The value EUD2, 
deﬁ ned with regard to dosage fractionation and 
the linear-quadratic relationship, averages 11% 
less than EUD1, which is deﬁ ned on the basis of 
the model SF(D) = exp(-D/Do).
Any possible use of EUD as a criterion for the 
optimisation of dose distribution must be pre-
ceded by the convinced application of this pa-
rameter in clinical practice. The parameter EUD 
has aroused great interest and many authors be-
lieve that EUD values are connected to clinical 
results [15,16].
In 1999 Niemierko proposed the general con-
cept of EUD [17]. According to that idea, EUD 
may be shown as a pure phenomenological ex-
pression:
EUD = (S
i
 V i D
a
i)
1/a
where Vi is the fraction of the total irradiated vol-
ume, dose is Di, and the parameter a (not to be 
confused with the LQ parameter) is speciﬁ c data 
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for neoplastic tissue, healthy tissues or organs at 
risk and is associated with the effects on those 
tissues in the volume to be irradiated. This for-
mula for EUD is applicable equally for tumours 
and for healthy tissues. EUD for neoplastic tissue 
behaves as already discussed while in healthy tis-
sues it is the uniform dose, which gives the same 
likelihood of complications as analysis of non-
uniform dose. For a=1, EUD is the arithmetical 
average of dose distribution.
CONCLUSIONS
The deﬁ nition of rules for planning implants 
in CNS brachytherapy, based on values of cov-
erage index and conformity factors is justiﬁ ed. 
Stereotactic implants, in comparison with classic 
Paris System implants, affect only half as much 
healthy tissue in the region of the reference isod-
ose. The high dose volume, however, is greater. 
The EUD model is a realistic alternative to the 
TCP and NTCP models. The parameter EUD, 
which is associated with the fraction of surviv-
ing cells in an irradiated volume, is a measure of 
the effectiveness of dose distribution. However, 
before optimisation of dose distribution can be 
based on EUD in practice, convincing clinical 
data must conﬁ rm that EUD is better than oth-
er parameters for describing the effects of radi-
otherapy.
REFERENCES:
 1. Niemierko A: Reporting and analyzing dose 
distributions: A concept of equivalent uniform 
dose. Med Phys, 1997; 24: 103–9
 2. Dosimetry of interstitial brachytherapy sourc-
es: Recommendations of the AAPM Radiation 
Therapy Committee Task Group No. 43. Med. 
Phys, 1995; 22: 209–35
 3. Lee E, Zaider M: On the determination of 
an effective planning volume for permanent pros-
tate implants. Int J Radiat Oncol Biol Phys, 2001; 
49: 1197–206
 4. Joiner M: Models of radiation cell killing. 
Basic clinical radiobiology. Steel G. (red). Arnold, 
Londyn, 1997, 52–57
 5. Prescribing, recording and reporting pho-
ton beam therapy. International Commission on 
Radiation Units and Measurements. Report 50, 
Washington DC, 1993
 6. Brahme A: Dosimetric precision requirements 
in radiation therapy. Acta Radiol Oncol, 1984; 23: 
379–91
 7. Code of practice for brachytherapy physics: 
Report of the AAPM Radiation Therapy Committee 
Task Group No. 56. Med Phys, 1997; 24: 1558–95
 8. Worwa B, Schmitt H, Sturm V: Incidence of late 
radiation necrosis with transient mass effect after in-
terstitial low dose rate radiotherapy for cerebral gli-
omas. Acta Neurochir (Vien), 1989; 99: 104–8
 9. Brenner D: Dose, volume and tumor-control 
predictions in radiotherapy. Int J Radiat Oncol Biol 
Phys, 1992; 26: 171–79
 10. Vikram B, Deore S, Beitler J et al: The relationship 
between dose heterogeneity (“hot spots”) and com-
plications following high dose rate brachytherapy. 
Int J Radiat Oncol Biol Phys, 1999; 43: 983–87
 11. Ling C, Chui Ch: Stereotactic treatment of brain tu-
mors with radioactive implants or external photon 
beams: radiobiophysical aspects. Radiother Oncol, 
1993; 26: 11–18
 12. Deasy J, Chao C, Markman J: Uncertainties in 
model-based outcome predictions for treatment 
planning. Int J Radiat Oncol Biol Phys, 2001; 51: 
1389–99
 13. Wu Q, Mohan R, Niemierko A: Optimization of 
intensity-modulated radiotherapy plans based on 
the Equivalent Uniform Dose. Int J Radiat Oncol 
Biol Phys, 2002; 52: 224–35
 14. Maciejewski B: Dose, Time & Fractionation 
Conference: Biological & Physical Basis of IMRT 
& Tomotherapy. Nowotwory, 2001; 51: 619–22
 15. Terahara A, Niemierko A, Goitein M et al: Analysis 
of the relationship between tumor dose inhomoge-
neity and local control in patients with skull base 
chordoma. Int J Radiat Oncol Biol Phys, 1999; 45: 
351–58
 16. Chao K, Deasy J, Markman J et al: A prospective 
study of salivary function sparing in patients with 
head-and-neck cancers receiving intensity-modu-
lated or three-dimensional radiation therapy: ini-
tial results. Int J Radiat Oncol Biol Phys, 2001; 49: 
907–16
 17. Niemierko A: A generalized concept of Equivalent 
Uniform Dose. Med Phys, 1999; 26: 1100
Original Paper Rep Pract Oncol Radiother, 2005; 10(6): 285-292
292
